KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Chemed (CHE) Common Equity (2016 - 2025)

Chemed (CHE) has 17 years of Common Equity data on record, last reported at $979.4 million in Q4 2025.

  • For Q4 2025, Common Equity fell 12.47% year-over-year to $979.4 million; the TTM value through Dec 2025 reached $979.4 million, down 12.47%, while the annual FY2025 figure was $979.4 million, 12.47% down from the prior year.
  • Common Equity reached $979.4 million in Q4 2025 per CHE's latest filing, down from $1.1 billion in the prior quarter.
  • Across five years, Common Equity topped out at $1.2 billion in Q3 2024 and bottomed at $623.3 million in Q4 2021.
  • Average Common Equity over 5 years is $960.8 million, with a median of $965.7 million recorded in 2023.
  • Peak YoY movement for Common Equity: tumbled 30.84% in 2021, then surged 41.28% in 2023.
  • A 5-year view of Common Equity shows it stood at $623.3 million in 2021, then increased by 28.15% to $798.7 million in 2022, then skyrocketed by 38.71% to $1.1 billion in 2023, then grew by 1.0% to $1.1 billion in 2024, then decreased by 12.47% to $979.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $979.4 million in Q4 2025, $1.1 billion in Q3 2025, and $1.2 billion in Q2 2025.